Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a sell rating to a hold rating in a research report released on Saturday.

MAZE has been the topic of a number of other research reports. BTIG Research lifted their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. HC Wainwright boosted their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company started coverage on Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective on the stock. Finally, Wedbush boosted their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $41.88.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE opened at $39.71 on Friday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $43.29. The business has a 50-day moving average of $33.58 and a two-hundred day moving average of $22.27. The stock has a market capitalization of $1.91 billion and a P/E ratio of -1.90.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $45,460,000. ARCH Venture Management LLC bought a new position in Maze Therapeutics in the first quarter worth $45,362,000. Matrix Capital Management Company LP bought a new position in Maze Therapeutics in the first quarter worth $27,373,000. Woodline Partners LP acquired a new stake in Maze Therapeutics during the first quarter worth $10,229,000. Finally, Vanguard Group Inc. increased its holdings in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the period.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.